Sun Pharma reports Q2 net profit at ₹3,040 Crore

29 Oct 2024 , 10:30 AM

Sun Pharmaceuticals Ltd., India’s largest pharmaceutical company, posted a net profit of ₹3,040 Crore on Monday, October 28. Revenue for the quarter was ₹13,291 Crore.

EBITDA stood at ₹3,939 Crore, with a margin of 29.6%, lower than the estimated 30%.

For the reporting quarter, US formulation sales increased 20% year on year to $517 million, accounting for 33% of overall sales. The developing markets revenues totalled $293 million in the September quarter, up 3% year on year.

Formulation sales in the Rest of the World (ROW) markets fell 3% year on year to $199 million in Q2FY25.

API’s external sales increased 7% year on year to ₹534 Crore in the second quarter.

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun, pending approval. With Fibromun, it has increased its product offering for dermatologists. 

In Q2, India’s formulation sales totalled ₹4,265 Crore, up 11% from the same period of the previous year and accounting for 32% of overall consolidated sales. In the first half, revenues totalled ₹8,409.7 Crore, up 13.6% from the same period last year.

For feedback and suggestions, write to us at [e-mail]